全球静脉注射铁剂市场规模、份额、趋势和成长分析报告（2026-2034年）

预计静脉注射铁剂市场将从 2025 年的 26 亿美元成长到 2034 年的 48.3 亿美元，2026 年至 2034 年的复合年增长率为 7.12%。

随着慢性肾臟病、肿瘤和发炎性肠道疾病等慢性疾病中缺铁性贫血的诊断率不断上升，静脉铁剂市场正迅速成长。由于静脉铁剂比口服铁剂更快补充铁蕴藏量，因此在需要快速改善病情或口服治疗无效时，静脉注射铁剂是临床上的首选。医院静脉输液服务的扩展以及针对特定患者群体推荐使用静脉铁剂的指南的更新，都促进了静脉铁剂使用量的增长。

关键驱动因素包括慢性病盛行率上升、贫血筛检通讯协定改善以及临床医生对静脉铁剂疗效和安全性的认识不断提高。新型製剂可实现高剂量单次给药并缩短输注时间，提高了给药的可行性和患者的便利性，从而加速了住院和门诊输液中心对静脉铁剂的推广应用。成本趋势和支付方政策仍然是重要的影响因素；有利的报销方案和明确的指南建议能够促进静脉铁剂的推广应用，而有限的保险覆盖范围则可能减缓其普及。

展望未来，由于人口结构变化导致合格的患者群体增加，以及研发公司推出耐受性更好、给药更便捷的製剂，预计市场将进一步扩张。生物相似药的上市和价格竞争压力将有助于提高药物可及性，而以降低住院率和输血率为评估指标的价值医疗模式，如果静脉铁剂疗法的成本效益得到证实，则将更受青睐。製药公司与输液服务提供者之间的策略合作可以进一步简化给药流程和后续的患者追踪。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球静脉注射铁剂产品市场：依药物类型划分

• 市场分析、洞察与预测
• 聚葡萄糖铁
• 蔗糖铁
• 羧基Carboxymaltose铁
• 其他药物类型

第五章：全球静脉注射铁剂产品市场：依应用划分

• 市场分析、洞察与预测
• 慢性肾臟病
• 发炎性肠道疾病
• 癌症
• 其他用途

第六章：全球静脉注射铁剂产品市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球静脉注射铁剂产品市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AbbVie Inc
  • AdvaCare Pharma
  • Akebia Therapeutics Inc
  • AMAG Pharmaceuticals Inc
  • Bayer AG
  • Covis Pharma GmbH
  • CSL Limited
  • Daiichi Sankyo Company Ltd
  • F. Hoffmann-La Roche Ltd
  • Fresenius SE & Co. KGaA
  • Novartis AG
  • Pharmacosmos A/S

The Intravenous Iron Drugs Market size is expected to reach USD 4.83 Billion in 2034 from USD 2.60 Billion (2025) growing at a CAGR of 7.12% during 2026-2034.

The intravenous iron drugs market has grown rapidly in response to higher diagnosis rates of iron-deficiency anemia across chronic diseases such as chronic kidney disease, oncology, and inflammatory bowel disease. IV iron formulations allow faster repletion of iron stores than oral supplements, making them clinically preferred in settings where rapid correction is needed or oral therapy fails. Expansion of hospital-based infusion services and evolving guideline endorsements for IV iron in specific patient populations have contributed to increased utilization.

Drivers include rising chronic disease prevalence, better anemia screening protocols, and broader clinician acceptance of IV iron's efficacy and safety. Newer formulations that allow higher single-dose administration and reduced infusion times improve logistical feasibility and patient convenience, encouraging adoption in both inpatient and outpatient infusion centers. Cost dynamics and payer policies remain important variables-favorable reimbursement and clear guideline recommendations accelerate uptake, whereas restrictive coverage can slow access.

Looking ahead, the market is set to expand as demographic shifts increase the pool of eligible patients and as developers introduce formulations with improved tolerability and dosing convenience. Biosimilar entrants and competitive pricing pressures could broaden access, while value-based care models that reward reduced hospitalization and transfusion rates will favor IV iron therapies when cost-effectiveness is demonstrated. Strategic alliances between drug manufacturers and infusion providers may further streamline delivery and patient follow-through.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Drug Types

By Application

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• AbbVie Inc, AdvaCare Pharma, Akebia Therapeutics Inc, AMAG Pharmaceuticals Inc, Bayer AG, Covis Pharma GmbH, CSL Limited, Daiichi Sankyo Company Ltd, F HoffmannLa Roche Ltd, Fresenius SE Co KGaA, Novartis AG, Pharmacosmos AS
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Iron Dextran Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Iron Sucrose Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Ferric Carboxymaltose Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Drug Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Chronic Kidney Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Inflammatory Bowel Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL INTRAVENOUS IRON DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 AdvaCare Pharma
  • 9.2.3 Akebia Therapeutics Inc
  • 9.2.4 AMAG Pharmaceuticals Inc
  • 9.2.5 Bayer AG
  • 9.2.6 Covis Pharma GmbH
  • 9.2.7 CSL Limited
  • 9.2.8 Daiichi Sankyo Company Ltd
  • 9.2.9 F. Hoffmann-La Roche Ltd
  • 9.2.10 Fresenius SE & Co. KGaA
  • 9.2.11 Novartis AG
  • 9.2.12 Pharmacosmos A/S